Internationaler Experten-Konsensus zum Einsatz von AboBotulinumtoxin A (AboTA) zur Gesichtsverjüngung und bei primärer Hyperhidrose

International expert consensus on the use of AboBotulinum Toxin A (AboTA) for facial rejuvenation and primary hyperhidrosis

Keywords | Summary | Correspondence | Literature


, , , ,


, , , , , ,


Introduction: Recent developments in our understanding of facial ageing have led to a greater appreciation of the part played by dynamic wrinkles. Botulinum toxin is increasingly used to lessen hyperdynamic muscular activity and to rejuvenate the ageing face. Materials and method: A group of international experts convened to consider the literature and, in the light of their own clinical experience, discuss the optimal uses of abobotulinum toxin A (aboTA) for myomodulation. To assist doctors, the international expert group here presents consensus guidelines for the use of AboTA in various clinical indications. Discussion: To achieve optimal results, the clinician requires a detailed understanding of facial anatomy, correct dilution technique, injection procedure and aftercare. Conclusions: AboTA may be used to rejuvenate the face and other areas. AboTA treatment is effective, safe, and relatively easy to perform and has high patient satisfaction. Duration of action is up to 5 1/2 months.


Einführung: Die jüngsten Entwicklungen in unserem Verständnis der Gesichtsalterung haben dazu geführt, dass die Rolle dynamischer Falten stärker wahrgenommen wird. Botulinumtoxin wird zunehmend eingesetzt, um die hyperdynamische Muskeltätigkeit zu vermindern und das alternde Gesicht zu verjüngen. Materialien und Methode: Eine Gruppe internationaler Experten traf sich, um die Literatur zu prüfen und anhand ihrer eigenen klinischen Erfahrungen über die optimale Verwendung von Abobotulinumtoxin A (AboTA) zur Myomodulation zu diskutieren. Daraus resultieren die vorliegenden Empfehlungen der internationale Expertengruppe in Form eines Experten-Konsensus für den Einsatz von AboTA in verschiedenen klinischen Indikationen. Diskussion: Um optimale Ergebnisse zu erzielen, benötigt der Arzt ein detailliertes Verständnis der Anatomie des Gesichtes, der richtigen Verdünnungstechnik des Präparates, des Injektionsverfahrens und der Nachsorge. Schlussfolgerung: AboTA kann zur Verjüngung des Gesichtes und anderer Bereiche verwendet werden. Die AboTA-Behandlung ist effektiv, sicher, relativ einfach durchzuführen und hat eine hohe Patientenzufriedenheit. Die Wirkdauer beträgt bis zu 5 1/2 Monaten.

Leider haben Sie sich nicht eingeloggt, um den Beitrag lesen zu können. Bitte loggen Sie sich ein oder beantragen Sie Ihre Zugangsberechtigung. Vielen Dank. Weitere Informationen finden Sie hier>


Prof. Alessio Redaelli, M.D.
Via delle Repubblica 4
I-20098 San Giuliano Milanese

Conflict of Interests

Redaelli A, Saromytskaya A, Panova O, Atamanov V, Kobaladze N, Gavashely L, Goltsova E, Sanches E, Gubanova E, Orlova O, Reznik A, Lukyanau A, Sharova A, Zhaboeva S, Holod O, Zhumatova G, Soikher M, Shelekhov S, Saromytskaya A sind Trainer und Sprecher für die Firma Ipsen Pharma. Landau M, Atamanov V, Gubanova E sind Trainer und Sprecher für die Firma Galderma. Kobaladze N, Diaspro A, Zhaboeva S, Gavasheli L are trainers for Aptos Company Sanches E is medical adviser of the company Oftaderm Orlova O is trainer and speaker for Allergan, Martinex, Microgen and Merz Aesthetics Companies Reznik A is speaker and trainer for the Institute Hyalual Company Sharova A is trainer and speaker for Innovation and LG company Goltsova E is trainer and speaker for the Merz Aesthetics Companies Redaelli A, Zhumatova G are trainers and speakers for Filorga company Rowland Payne C is a key opinion leader for Venn and an occasional speaker for Ipsen & Sesderma. Battistella M is trainer and speaker for General Project, Wavemed, Attiva, Venus Concept Companies


1. Redaelli A, Braccini F (eds).: Facial aging. Medical, surgical and odontostomatological solutions for mid & inferior part of the face. Florence: Officina Editoriale Oltrano: 2012.
2. Wollina U, Rowland Payne C (2010) Aging well-the role of minimally invasive aesthetic dermatological procedures in women over 65. J Cosmet Dermatol 9(1): 50-8.
3. Wollina U. Botulinum toxins: uses in medicine. Cosmetic medicine and surgery. Ed: Andrè P, Haneke E, Marini L, Rowland Payne C. Boca Raton, FL: CRC Press, pp 547-5.
4. Wollina U (2008) Botulinum toxin: Non-cosmetic indications and possible mechanisms of action. J Cutan Aesthet Surg 1(1): 3-6.
5. Cohen JL, Scuderi N (2017) Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use: a systematic review of clinical studies. Aesthet Surg J 5: 37(suppl_1): S32-S44.
6. Schlessinger J (2014) Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study. Dysport Study Group. Dermatol Surg. 40(2): 176-83.
7. Lorenc ZP (2013) A review of AbobotulinumtoxinA (Dysport). Aesthet Surg J 33 (1 Suppl):13S-7S.
8. Fabi SG (2013) A two-center, open-label, randomized, split-face study to assess the efficacy and safety of one versus three intradermal injection sites of abobotulinumtoxinA in the treatment of lateral periocular rhytides. J Drugs Dermatol 12(8): 932-7.
9. Erickson BP (2015) The role of neurotoxins in the periorbital and midfacial areas. Facial Plast Surg Clin North Am 23(2): 243-55.
10. Klein FH (2014) Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol. 89(6): 878-84.
11. Redaelli A (2011) Botulinum toxin A in bruxers: one year experience. Saudi Med J 32(2): 156-158.
12. Redaelli A (2014) BTxA in aesthetic Medicine, for hyperhidrosis and in odontostomatology. Basic Principles and clinical practice. Second revised edition, OEO Firenze.
13. Kiripolsky MG, Goldman MP (2011) Safety and efficacy of administering abobotulinumtoxinA through a single injection point when treating lateral periocular rhytides. J Cosmet Dermatol 10(3): 232-234.
14. Rzany B (2006) Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 142(3): 320-6.
15. Hexsel D (2013) Quality of life and satisfaction of patients after full-face injections of abobotulinum toxin type A: A randomized, phase IV clinical trial. J Drugs Dermatol 12(12): 1363-7.
16. Kim BW (2014) Adverse events associated with botulinum toxin injection: a multidepartment, retrospective study of 5310 treatments administered to 1819 patients. J Dermatolog Treat 25(4):331-6.
17. Yin-Shuo Chang (2015) Nonallergic eyelid edema after botulinum toxin type A injection. Case report and review of literature. Medicine (Baltimore). 94(38): e1610.
18. Saban I (2016) Anatomie du visage et du cou en chirurgie et cosmetology. Elsevier Masson.
19. Wollina U (2005) Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol 6(3): 141-50.
20. Punga AR, Alimohammadi M, Fagrell D, Nyberg F, Rees D, Wong C (2016) A randomized, comparative study to evaluate efficacy and safety of 2 injection volumes of abobotulinumtoxinA in treatment of glabellar lines. Dermatol Surg 42(8): 967-76.
21. Frevert (2015) Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. J Drugs Res Derm 15(1): 1-9.
22. Kassir R, Kollurur A, Kassir M (2013) Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxinA and onabotulinumtoxinA for the treatment of facial rhytids. Dermatol Ther 3(2): 179-89.
23. Yu KC, Nettar KD, Bapna S, Boscardin WJ, Maas CS (2012) Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg 14(3): 198-204.
24. Scaglione F (2016) Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel) 2016 8(3).
25. Naumann M (2013) Immunogenicity of botulinum toxins. J Neural Transm (Vienna) 120(2): 275-90.
26. Rubin MG Cox SE, Kaminer MS, Solish N (2014) Correcting age-related changes in the face by use of injectable fillers and neurotoxins. Semin Cutan Med Surg 33(4 Suppl): S81-4.
27. Redaelli A (2012) Minimally invasive procedures for nasal aesthetics. J Cutan Aesthet Surg 25(2): 115-20.
28. Rowland Payne CME (2012) Multi-mini botulinum. Chapter in: Botulinum toxin A in aesthetic medicine. Eds. Redaelli A, Braccini F. Officina Editoriale Oltrarno S.r.l – Firenze, 185-198.
29. Rowland Payne CME (2016) Cosmetic botulinum toxin treatment. In: Andre P, Haneke E, Marini L & Rowland Payne CME, editors. Cosmetic Medicine & Surgery. 1st ed. Taylor & Francis-CRC Press (London); p. 557-80.
30. Rowland Payne CME (2016) Complications & pitfalls of cosmetic botulinum. In: Andre P, Haneke E, Marini L & Rowland Payne CME, editors. Cosmetic Medicine & Surgery. 1st ed. Taylor & Francis-CRC Press (London); p. 581-89.
31. Rowland Payne CME (2017) Cosmetic dermatology of the nose and medical rhinoplasty. Aesthetic Surgery Techniques – A Case Based Approach. Elsevier. In press.
32. Jandhyala R (2012) Effectiveness of type A botulinum toxins for aesthetic indications and their relative economic impact. J Plast Reconstr Aesthet Surg 65(6): 720–731.



Passwort vergessen?